eTheRNA’s goal is to commercialize mRNA-based immunotherapies as off-the-shelf products for the treatment of cancer and infectious diseases.
To fight cancer, eTheRNA adopts multiple strategies including :
New, pioneering immunotherapies using proprietary TriMix mRNA technology to stimulate and educate dendritic cells to create a potent, durable T-cell-mediated immune response against tumors in specific cancer indications. Different routes of administration (intranodal and intravenous) and different sources of antigens (tumor-associated antigens, viral antigens and shared neoantigens) are being deployed in different combinations in multiple development programs.
An innovative mRNA mix that mimics the action of oncolytic viruses to induce immunogenic death of tumor cells and renders the tumor more susceptible towards the anti-tumor T cell response
The different approaches can be combined with each other and other classes of treatment interventions.
To fight infectious diseases, eTheRNA is adapting its proprietary
TriMix technology to a product that can be administered intranasally and lead to antigen-specific T-cell-mediated mucosal immunity. This new approach is being applied to vaccines to protect against upper respiratory tract viruses including CoV-19 (coronavirus).
IN naked mRNA vaccine for melanoma
Phase I / II
LNP based E6E7 vaccine
IT optimized TriMix
Cell death induction
To be determined
ID / autoimmune
© 2020 Etherna | Studio Hanswijk